Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Kymera Therapeutics, Inc. Common Stock

KYMR

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Last trade $122.12
Day change -$3.735 (-2.97%)
Day range $119.57 – $126.07
Volume 442,673
Market cap $10.74B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.74B
Price / earnings
—
Price / book
6.65×
Price / sales
105.09×
EV / sales
101.46×
EV / EBITDA
-26.14×

Profitability

Earnings per share
-$4.09
Return on assets
-19.77%
Return on equity
-21.64%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
11.13×
Quick ratio
11.13×
Cash ratio
4.16×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$288.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KYMR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$65M$34.37M$2.87M$2.76M$11.48M$22.1M$7.39M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$65M$34.37M$2.87M$2.76M$11.48M$22.1M$7.39M
Selling, general and administrative$18.72M$21.13M$20.36M$16.94M$17.34M$17.65M$16.27M$16.33M
Research and development$128.51M$119.48M$98.16M$83.83M$74.09M$78.39M$80.26M$71.82M
Total operating expenses$147.23M$140.61M$118.58M$100.77M$95.29M$96.03M$96.6M$88.15M
Operating income-$147.23M-$75.61M-$84.22M-$97.9M-$92.52M-$84.56M-$74.5M-$80.76M
Interest expense-$62K$14.48M$0$280K-$98K$8.05M$0$190K
Income before taxes-$132M-$61.21M-$69.23M-$86.98M-$82.18M-$76.61M-$65.58M-$70.75M
Income taxes$0$0$0$0$0$0$0$0
Net income-$132M-$61.21M-$69.23M-$86.98M-$82.18M-$76.61M-$65.58M-$70.75M
Net income attributable to common shareholders-$132M-$61.21M-$69.23M-$86.98M-$82.18M-$76.61M-$65.58M-$70.75M
EBITDA-$145.21M-$73.58M-$82.19M-$95.86M-$86.52M-$82.47M-$72.45M-$78.77M
Basic earnings per share-$1.32-$0.62-$0.71-$0.97-$0.94-$0.95-$0.82-$0.88
Diluted earnings per share-$1.32-$0.62-$0.71-$0.97-$0.94-$0.95-$0.82-$0.88

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

Kymera Therapeutics reported Q3 2026 financial results with positive Phase 1 data for KT-579 (IRF5 degrader) showing deep, sustained target degradation and favorable safety profile. The company is advancing KT-621 (STAT6 degrader) in Phase 2b trials for atopic dermatitis and asthma, with AD topline data expected by year-end 2026. Kymera maintains strong financial position with $1.6 billion in cash providing runway into 2029.

Zacks Investment Research

Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know

Axsome Therapeutics is expected to report a quarterly loss of $0.65 per share with revenues of $249.32 million when it releases Q3 2026 earnings on November 2. However, analyst estimates have been revised 70.27% lower over the last 30 days, and the company's Earnings ESP of -11.79% combined with a Zacks Rank #3 makes it difficult to predict an earnings beat. The company has failed to beat consensus EPS estimates in the last four quarters.

Zacks Investment Research

Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?

Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026. Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space.

The Motley Fool

Kymera's CEO Sold $6 Million in Stock After a 170% Run

Kymera Therapeutics CEO Nello Mainolfi sold 50,000 shares for $6 million on July 7, 2026, following a 170% stock surge over 12 months. The sale involved exercising options at $2.08 and selling at $119 per share under a pre-scheduled Rule 10b5-1 trading plan. Despite the sale, Mainolfi retains 666,568 shares worth $79.5 million and 90,000 options, indicating continued confidence in the company's pipeline, particularly KT-621 in Phase 2b trials with FDA Fast Track status.

GlobeNewswire Inc.

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Kymera Therapeutics announced Phase 1 results for KT-621, a first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The data showed consistent safety and pharmacokinetic/pharmacodynamic profiles with previous studies, demonstrating rapid and sustained STAT6 degradation (≥98% at Day 7). The company has parallel Phase 2b trials ongoing in atopic dermatitis (BROADEN2) and asthma (BREADTH), with data expected by mid-2027 and late 2027, respectively.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.